Advancing Kinase Drug Discovery with Eurofins Discovery

Advanced modalities like PROTACs, molecular glues, and Antibody Drug Conjugates (ADCs) are redefining the boundaries of drug discovery.

Kinase drug discovery is complex due to conserved ATP binding pockets and high structural homology, making selectivity and mechanism of action assessment particularly challenging. To support rapid, confident decision making, Eurofins Discovery provides a comprehensive suite of kinase platforms that deliver high quality data across binding, activity, cellular context, and mechanistic profiling.

Broad Kinome Insight with KINOMEscan^®

KINOMEscan uses a site directed competition binding assay to quantify interactions across over 500 kinase domain-containing wildtype and clinically relevant mutant targets. It supports multiple compound modalities (small molecules, peptides, conjugates, covalent inhibitors, and bifunctional degraders) and offers fast turnaround to maintain project momentum.

TREEspot^® data visualization tool enables clear visualization of kinome-wide binding and efficient identification of differentiated selectivity profiles.

Functional Potency with KinaseProfiler^™

To complement binding data, KinaseProfiler measures functional activity across 450+ biologically relevant kinases using radiometric, luminescence, and TR FRET technologies. Researchers can select ATP conditions (10 µM, Km, or 1 mM) to model biological scenarios more accurately.

A guaranteed six business day turnaround supports rapid SAR cycles, hit validation, and early derisking of lead candidates.

Strengthening Biological Relevance

Eurofins Discovery adds key layers of physiological and mechanistic insight:

• Cell based tyrosine and cytosolic kinase assays assess RTK and CTK signaling, membrane permeability, and ATP level competition under native cellular conditions, across 100+ kinase targets.
• Over 550 recombinant kinase drug targets, including active, inactive, and mutant forms, support screening, mechanistic characterization, and QC workflows.
• BRET based target engagement assays enable measurement of affinity in a cellular environment across 350+ full length kinases, offering deeper mechanistic understanding.

These complementary tools help researchers move beyond simple inhibition measurements toward more complete pharmacological profiling.

A Smooth, Science Driven Customer Journey

Eurofins Discovery’s kinase solutions are designed for efficiency and clarity:

• Fast timelines, supported by optimized workflows, provide some of the quickest reporting standards for binding and activity profiling.
• Flexible, scalable testing, enabling single assays or broader profiling depending on phase and budget.
• Intuitive visualization, with TREEspot helping teams quickly interpret kinome-wide data.

This combination of scientific depth and operational reliability supports an experience where researchers learn more and progress faster.

Discover our Kinase solutions here:

https://apac.eurofinsdiscovery.com/solution/kinases